EW Q4 2024 Earnings — Edwards Lifesciences Corporation Revenue & Financial Results | Market Cap Arena

EWEdwards Lifesciences Corporation

$50B

Q4 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$1.4B+9.4% YoY

Gross Profit

$1.1B78.9% margin

Operating Income

$313M22.6% margin

Net Income

$386M27.8% margin

EPS (Diluted)

$0.65

QoQ Revenue Growth

+2.3%

Cash Flow

Operating Cash Flow

-$128M

Free Cash Flow

-$177M

Stock-Based Comp.

$51M

Balance Sheet

Total Assets

$13.1B

Total Liabilities

$3.0B

Stockholders' Equity

$10.0B

Cash & Equivalents

$3.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.4B	$1.3B	+9.4%
Gross Profit	$1.1B	$1.0B	+7.7%
Operating Income	$313M	$357M	-12.4%
Net Income	$386M	$370M	+4.2%

Revenue Segments

Transcatheter Heart Valves

$1.0B77%

Surgical Heart Valve Therapy

$211M16%

Transcatheter Mitral And Tricuspid Therapies

$105M8%

Geographic Segments

UNITED STATES

$644M58%

Europe

$299M27%

Rest of World

$98M9%

JAPAN

$60M5%